ACE and liver cancer: In addition, we compared the ability of LUC7L3 with the existing liver cancer biomarkers AFP and DCP to stratify HCC patients (Figure S1B), showing that they had similar abilities in predicting the prognosis of patients with full-stage HCC (Gao’s cohort and Xing’s cohort).